Overview

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott